CDK12 and neoplasm: Both CDK12-KI/PyMT and CDK12-KI/NeuN female mice showed significantly increased tumor multiplicity and average tumor size, and reduced tumor-free survival rate, compared to their respective WT/PyMT and WT/NeuN controls (Fig. 2a–c, Supplementary Fig. 2a–c).